                               SEQUENCE LISTING

<110> ALLEGRO PHARMACEUTICALS, LLC
 
<120> INHIBITION OF TUMOR NECROSIS FACTOR, PRO-INFLAMMATORY CYTOKINES 
      AND OTHER INFLAMMATORY RESPONSE MEDIATOR

<130> ALLEG-021PC

<140> PCT/US2022/022316
<141> 2022-03-29

<150> 63/167,879
<151> 2021-03-30

<160> 6     

<170> PatentIn version 3.5

<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 1
Gly Arg Gly Ala Thr Pro 
1               5       


<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (3)..(3)
<223> Cysteic acid

<400> 2
Arg Gly Xaa Gly Gly Gly Asp Gly 
1               5               


<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (3)..(3)
<223> Cysteic acid

<400> 3
Arg Gly Xaa Phe Val 
1               5       


<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 4
Arg Gly Asp Asp Phe Val 
1               5           


<210> 5
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (4)..(4)
<223> Cysteic acid

<400> 5
Gly Arg Gly Xaa Thr Pro 
1               5       


<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(3)
<223> This region may encompass one of the following sequences:
      Phe-Val-Ala, Phe-Leu-Ala, Phe-Val-Gly, Phe-Leu-Gly, 
      Phe-Pro-Gly, Phe-Pro-Ala or Phe-Val

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Cysteic acid

<220>
<221> MOD_RES
<222> (7)..(9)
<223> This region may encompass one of the following sequences:
      Phe-Val-Ala, Phe-Leu-Ala, Phe-Val-Gly, Phe-Leu-Gly, 
      Phe-Pro-Gly, Phe-Pro-Ala or Phe-Val 

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 6
Xaa Xaa Xaa Arg Gly Xaa Xaa Xaa Xaa 
1               5                   


